The Lancet

Actualizado 25.05.2020


Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Sharpening the global focus on ethnicity and race in the time of COVID-19

Artículos anteriores

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

A history of the medical mask and the rise of throwaway culture

Who is most likely to be infected with SARS-CoV-2?

Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study

Offline: A global health crisis? No, something far worse

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Effect of the COVID-19 pandemic on cancer treatment and research

Mitigating the effect of the COVID-19 pandemic on sickle cell disease services in African countries

Impact of school closures for COVID-19 on the US health-care workforce and net mortality: a modelling study

Cancer guidelines during the COVID-19 pandemic

Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection

COVID-19: protecting health-care workers

COVID-19: the medium is the message

COVID-19 and Italy: what next?

Preparedness is essential for malaria-endemic regions during the COVID-19 pandemic

Un viaje a través de artículos publicados en medios del sector sanitario